Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus PROMETHAZINE HYDROCHLORIDE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus PROMETHAZINE HYDROCHLORIDE PLAIN.
ANTIVERT vs PROMETHAZINE HYDROCHLORIDE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also has anticholinergic, antiemetic, and sedative properties. In the CNS, it inhibits the chemoreceptor trigger zone and vestibular apparatus, contributing to its antiemetic effect.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
Adults: 25 mg orally or intramuscularly every 4 to 6 hours as needed; for motion sickness, 25 mg taken 30-60 minutes before departure, then every 12 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
Terminal elimination half-life is approximately 10-19 hours in adults (mean ~16 hours). In children, half-life is shorter (~7-14 hours). Clinical context: Once-daily dosing may be insufficient for continuous sedation; requires every 6-8 hour dosing for sustained effect.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~70% of elimination, with 20-30% as unchanged drug in urine. Fecal excretion is minimal (~5%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic